Biblio

Filters: Author is Qiu, Huiying [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

C

Li S, Ge J, Zhou S, Zhu W, Han Y, Chen S, Xue S, Wang Y, Qiu H, Wu X, et al. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr vir. Clin Transl Med. 2023;13(10):e1459.

Zhang Y, Liu L, Si Y, Miao M, Qiu H, Tang X, Han Y, Fu C, Jin Z, Chen S, et al. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. Hematology. 2021;26(1):741-750.

Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, Han Y, Fu Z, Qiu H, Sun A, et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res. 2016;45:40-46.

Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.

Liu L, Xu G, Zhang Y, Jiao W, Lei M, Zhou H, Wang Q, Qiu H, Tang X, Han Y, et al. Comparison of two different rabbit antithymocyte globulin (r-ATG) preparations:Thymocyte r-ATG versus T lymphoblast cell line r-ATG in allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: propensity score-matched analysi. Biol Blood Marrow Transplant. 2020.

E

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.

I

Jiang P, Cai Y, Zhou X, Yang J, Tong Y, Huang C, Qiu H, Zhou K, Xu X, Zhang Y, et al. Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors. Clin Transplant. 2022:e14844.

Zhou X, Jiang P, Gao L, Yang J, Cai Y, Tong Y, Qiu H, Huang C, Zhou K, Xu X, et al. Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT. Ann Hematol. 2022.

Jiang P, Yu F, Xu X, Cai Y, Yang J, Tong Y, Huang C, Qiu H, Zhou K, Zhang Y, et al. Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation. Cell Transplant. 2023;32:9636897231157054.

Wei X, Chang Y, Zhu X, Hu X, Guo R, Zhang Y, Ma X, Han Y, Wang Y, Qiu H, et al. The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: A multicenter study. HLA. 2023.

L

Li X, Yang J, Cai Y, Huang C, Xu X, Qiu H, Niu J, Zhou K, Zhang Y, Xia X, et al. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study. Front Immunol. 2023;14:1252879.

O

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.

R

Xiao J, Xie J, Zhou B, Liu Y, Lu J, Jiang A, Yao H, Qiu Q, Ding Z, Xue S, et al. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.

T

Fu C, Wang J, Xin X, Liu H, Xue S, Ma X, Jin Z, Sun A, Qiu H, Wu D. Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med. 2013;6(4):977-982.

V

Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.